70 results
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
15 Apr 21
Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of
4:11pm
diseases and vaccines global development, senior vice president of global scientific strategy (infectious disease, respiratory & immunology) and senior vice … development strategy that will ideally complement the board as Praxis’ portfolio continues to advance in the clinic. At the same time, we are deeply
8-K
EX-99.2
PRAX
Praxis Precision Medicines Inc
3 Nov 21
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2021 Financial Results
7:04am
) uncertainties and assumptions regarding the impact of the COVID-19 pandemic on our business, operations, clinical trials, supply chain, strategy … Hypoaesthesia Lethargy Myoclonus PRAX-562 (N=24) Placebo (N=8) * TEAEs related to blood sample collection excluded
PAGE 17 PRAX-562 development strategy
UPLOAD
PRAX
Praxis Precision Medicines Inc
19 Aug 20
Letter from SEC
12:00am
August 18, NamePraxis
2020 Precision Medicines, Inc.
August
Page 3 18, 2020 Page 3
FirstName LastName
Our Strategy, page 4
5 … . We note that you state your strategy is to "efficiently advance" your
product candidates
towards regulatory approval and commercialization
DRSLTR
PRAX
Praxis Precision Medicines Inc
28 Aug 20
Correspondence regarding draft registration statement
12:00am
or implications that the Company’s product candidates are effective.
Our Strategy, page 4
We note that you state your strategy is to “efficiently
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
9 May 22
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results
4:04pm
an overview of the Company’s proprietary innovation strategy, updates on its most advanced epilepsy programs and a review of the progress in Praxis … ’ business, operations, strategy, goals and anticipated timelines, Praxis’ ongoing and planned preclinical activities, Praxis’ ability to initiate
8-K
EX-99.2
g8wzi4j 5tt
11 May 21
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Results
8:11am
8-K
EX-99.2
ea2sbp0 llz
9 Nov 22
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:03pm
8-K
EX-99.2
b9gk hbv4jccatt
17 Mar 21
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
7:17am
8-K
EX-99.1
6ixl3hcg526t69 teoe
28 Nov 22
Regulation FD Disclosure
8:04am
8-K
EX-99.1
yrk5c1lpbyfv5
25 May 21
Praxis Precision Medicines Appoints Tim Kelly as Chief Financial Officer
8:04am
8-K
EX-99.1
m3pfie
17 Nov 20
Praxis Precision Medicines Provides Update On PRAX-114 IND Submission
4:01pm
8-K
EX-99.2
rhg3h
9 Nov 20
Regulation FD Disclosure
9:36pm
8-K
EX-99.1
wx4cgx
10 Jan 22
Regulation FD Disclosure
4:52pm
8-K
mh0b8
10 Jan 22
Regulation FD Disclosure
4:52pm
8-K
EX-99.2
op8qy 2wb
5 Mar 24
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7:13am
8-K
EX-99.1
03zb56cm5zd3odn9z
27 Apr 22
Regulation FD Disclosure
4:34pm
S-1
ea1t5yz2mhv zm3
25 Sep 20
IPO registration
5:19pm
8-K
EX-99.3
mwifj6w 8lyt
9 May 22
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results
4:04pm